Last reviewed · How we verify
Nucleoside Analog (Substance)
Nucleoside analogs inhibit viral or cancer cell replication by mimicking natural nucleosides and disrupting DNA/RNA synthesis.
At a glance
| Generic name | Nucleoside Analog (Substance) |
|---|---|
| Also known as | NAs |
| Sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Nucleoside analog |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Nucleoside analogs are synthetic compounds that structurally resemble natural nucleosides (building blocks of DNA and RNA). Once incorporated into nucleic acid chains during replication, they cause chain termination or introduce mutations, effectively halting the proliferation of rapidly dividing cells such as viruses or cancer cells. This mechanism makes them useful in both antiviral and anticancer therapy.
Approved indications
Common side effects
- Bone marrow suppression
- Gastrointestinal toxicity
- Hepatotoxicity
- Neuropathy
Key clinical trials
- Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection (PHASE2)
- Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia (PHASE3)
- The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: